Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glycotex, a biopharmaceutical company, has finalized an agreement with UK-based Advanced Medical Solutions, a developer of woundcare products, to study the use of GLYC-101 with wound dressings manufactured by AMS.
Subscribe to our email newsletter
Through this collaboration, Glycotex and Advanced Medical Solutions (AMS) have agreed to an initial phase of testing of the use of GLYC-101 with AMS’s wound dressings.
Under the agreement, in the event that this first phase of testing gives rise to favorable results, or generates data that suggest further research may be warranted, Glycotex and AMS will have an opportunity to extend their collaboration for the purposes of continued research.
GLYC-101 is intended to stimulate and modulate the natural cascade of wound healing activities of several cell populations. The product candidate currently under development is a topical gel to be applied directly on the wound surface. The strategic priorities for GLYC-101 include wound healing following laser ablation, burn wounds, surgical wounds, venous ulcers and diabetic ulcers.